MASH Treatment Global Market Opportunities And Strategies To 2034

Description

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is a chronic and progressive liver disease characterized by fat accumulation, inflammation and fibrosis in the liver, primarily linked to obesity, insulin resistance, type 2 diabetes and other metabolic disorders. The primary purpose of metabolic dysfunction-associated steatohepatitis (MASH) treatment is to halt or reverse liver damage, prevent disease progression to cirrhosis or liver failure, and manage associated metabolic conditions. The treatment typically includes lifestyle interventions, pharmacotherapy, and in some cases, surgical options to reduce liver inflammation, fibrosis, and metabolic risk factors.

The MASH treatment market consists of sales by entities (organizations, sole traders and partnerships) of MASH treatment drugs and therapy that is used when lifestyle modifications alone are insufficient to halt or reverse liver damage. It is utilized across a continuum of care, beginning with non-invasive interventions and progressing to pharmacological treatment or bariatric surgery in advanced cases.

The global MASH treatment market was valued at $978.91 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 21.00%.

Rising Research And Development (R&D) Spending In Life Sciences

Rising research and development (R&D) spending in life sciences fueled the growth of the MASH treatment in the historic period. MASH, a progressive liver disease linked to metabolic disorders like obesity and diabetes, has seen a surge in prevalence globally, driving pharmaceutical and biotech firms to invest heavily in novel therapeutics. Enhanced R&D funding has enabled breakthroughs in understanding disease mechanisms, such as lipid metabolism dysregulation, inflammation and fibrosis, leading to targeted drug development. Innovations in biomarkers, genetic research and preclinical models have accelerated drug discovery, while clinical trials for promising candidates like FXR agonists, THR-B agonists and GLP-1 receptor agonists have expanded. For instance, in July 2024, according to the GOV.UK, a UK-based government department, in 2022, the business enterprise sector conducted £9.0 billion ($11.7 billion) in pharmaceutical R&D, representing 0.36% of the UK's GDP. Pharmaceutical R&D made up 18% of all R&D carried out by businesses in the UK, the highest percentage among all product areas. Therefore, the rising research and development (R&D) spending in life sciences drove the growth of the MASH treatment market.

Advancements In Fibroblast Growth Factors (FGFs) Through Acquisitions

Major companies operating in the MASH treatment market are focusing on advancing fibroblast growth factor to strengthen their market position. Fibroblast growth factor 21 (FGF21) is a hormone-like protein that regulates lipid, glucose and energy metabolism in the body. FGF21 analogs have shown promise by reducing liver fat, inflammation and fibrosis, thus improving liver health and helping to resolve MASH without worsening fibrosis. These effects make FGF21-based therapies a leading strategy for addressing the metabolic and fibrotic complications of MASH. For example, in May 2025, GlaxoSmithKline (GSK), a UK-based pharma company acquired Efimosfermin (also known as efimosfermin alfa), a once-monthly fibroblast growth factor 21 (FGF21) from Boston Pharmaceuticals, a US-based pharma company. Efimosfermin is designed to provide direct antifibrotic action, aiming to reverse liver fibrosis and halt the progression of Metabolic Dysfunction-Associated Steatohepatitis (MASH), including cases that have advanced to cirrhosis. In addition to MASH, the therapy is being developed for alcohol-related liver disease (ALD) and both forms of steatotic liver disease (SLD), broadening its potential impact on serious liver conditions. GSK plans to explore efimosfermin both as a monotherapy and in combination with other investigational agents, including their siRNA therapeutic for liver disease. The acquisition and development of efimosfermin position GSK as a significant player in the evolving market for innovative liver disease therapies.

The global MASH treatment markets is fragmented, with large number of players operating in the market. The top 10 competitors in the market made up 9.15% of the total market in 2024.

MASH Treatment Global Market Opportunities and Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global MASH treatment market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for MASH treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The MASH treatment market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider MASH treatment market; and compares it with other markets.

The report covers the following chapters

Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment, by end user and by disease stage.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment, by end user and by disease stage in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size And Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments- Information on recent developments in the market covered in the report.
Market Opportunities And Strategies:- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations:- This section includes recommendations for MASH treatment market providers in terms of product/service offerings geographic expansion, marketing strategies and target groups
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Treatment: Drug; Therapy
2) By Disease Stage: Simple Fatty Liver / MASLD (No Or Mild Fibrosis); Early MASH (Significant/Advanced Fibrosis); Fibrotic MASH; MASH Cirrhosis And Liver Failure / Liver Cancer Mortality
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
Companies Mentioned: Madrigal Pharmaceuticals Inc.; Novo Nordisk A/S; Eli Lilly Company; AstraZeneca plc; Mayo Clinic
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; MASH treatment indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1749

1 Executive Summary

1.1 MASH Treatment - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 MASH Treatment Market Definition And Segmentations
6.4 Market Segmentation By Treatment
- 6.4.1 Drug
- 6.4.2 Therapy
6.5 Market Segmentation By Disease Stage
- 6.5.1 Simple Fatty Liver / MASLD (No Or Mild Fibrosis)
- 6.5.2 Early MASH (Significant/Advanced Fibrosis)
- 6.5.3 Fibrotic MASH
- 6.5.4 MASH Cirrhosis
- 6.5.5 Liver Failure / Liver Cancer Mortality
6.6 Market Segmentation By End-User
- 6.6.1 Hospitals
- 6.6.2 Specialty Clinics
- 6.6.3 Homecare
- 6.6.4 Other End-User

7 Major Market Trends

7.1 Advancements In Fibroblast Growth Factors (FGFs) Through Acquisitions
7.2 Integration Of Artificial Intelligence (AI) In MASH Treatment
7.3 Strategic Partnerships And Collaborations Among Market Players
7.4 Focus On Receiving Government Approvals To Highlight Advancements in MASH Treatment
7.5 Innovative MASH Treatments Address Fibrosis And Improve Liver Health Outcomes

8 MASH Treatment Growth Analysis And Strategic Analysis Framework

8.1 Global MASH Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
- 8.1.1 Political
- 8.1.2 Economic
- 8.1.3 Social
- 8.1.4 Technological
- 8.1.5 Environmental
- 8.1.6 Legal
8.2 Analysis Of End User Industries (B2B)
- 8.2.1 Hospitals
- 8.2.2 Specialty Clinics
- 8.2.3 Homecare
- 8.2.4 Other End-User
8.3 MASH Treatment Market Growth Rate Analysis
8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
- 8.4.1 Market Drivers 2019 - 2024
- 8.4.2 Market Restraints 2019 - 2024
8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
8.6 Forecast Growth Contributors/Factors
- 8.6.1 Quantitative Growth Contributors
- 8.6.2 Drivers
- 8.6.3 Restraints
8.7 MASH Treatment Total Addressable Market (TAM)

9 MASH Treatment Market Segmentation

9.1 MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 MASH Treatment Market, Sub-Segmentation Of Drug, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 MASH Treatment Market, Sub-Segmentation Of Therapy, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 MASH Treatment Market, Regional and Country Analysis

10.1 MASH Treatment Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 MASH Treatment Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

11.1 Summary
11.2 Market Overview
- 11.2.1 Region Information
- 11.2.2 Market Information
- 11.2.3 Background Information
- 11.2.4 Government Initiatives
- 11.2.5 Regulations
- 11.2.6 Regulatory Bodies
- 11.2.7 Major Associations
- 11.2.8 Taxes Levied
- 11.2.9 Corporate Tax Structure
- 11.2.10 Investments
- 11.2.11 Major Companies
11.3 Asia-Pacific MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific MASH Treatment Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
- 11.9.1 Country Information
- 11.9.2 Market Information
- 11.9.3 Background Information
- 11.9.4 Government Initiatives
- 11.9.5 Regulations
- 11.9.6 Regulatory Bodies
- 11.9.7 Major Associations
- 11.9.8 Taxes Levied
- 11.9.9 Corporate Tax Structure
- 11.9.10 Investments
- 11.9.11 Major Companies
11.10 China MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
- 11.19.1 Country Information
- 11.19.2 Market Information
- 11.19.3 Background Information
- 11.19.4 Government Initiatives
- 11.19.5 Regulations
- 11.19.6 Regulatory Bodies
- 11.19.7 Major Associations
- 11.19.8 Taxes Levied
- 11.19.9 Corporate Tax Structure
- 11.19.10 Investments
- 11.19.11 Major Companies
11.20 Japan MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.23 Australia Market
11.24 Australia MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.25 Australia MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.26 Australia MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.27 Indonesia Market
11.28 Indonesia MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Indonesia MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.30 Indonesia MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.31 South Korea Market
11.32 Summary
11.33 Market Overview
- 11.33.1 Country Information
- 11.33.2 Market Information
- 11.33.3 Background Information
- 11.33.4 Government Initiatives
- 11.33.5 Regulations
- 11.33.6 Regulatory Bodies
- 11.33.7 Major Associations
- 11.33.8 Taxes Levied
- 11.33.9 Corporate Tax Structure
- 11.33.10 Investments
- 11.33.11 Major Companies
11.34 South Korea MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.35 South Korea MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.36 South Korea MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate tax structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Western Europe MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe MASH Treatment Market: Country Analysis
12.7 UK Market
12.8 UK MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Major companies
13.3 Eastern Europe MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Eastern Europe MASH Treatment Market: Country Analysis
13.7 Russia Market
13.8 Russia MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.10 Russia MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 North America MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America MASH Treatment Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
- 14.9.1 Country Information
- 14.9.2 Market Information
- 14.9.3 Background Information
- 14.9.4 Government Initiatives
- 14.9.5 Regulations
- 14.9.6 Regulatory Bodies
- 14.9.7 Major Associations
- 14.9.8 Taxes Levied
- 14.9.9 Corporate Tax Structure
- 14.9.10 Investments
- 14.9.11 Major Companies
14.10 USA MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
- 14.15.1 Country Information
- 14.15.2 Market Information
- 14.15.3 Background Information
- 14.15.4 Government Initiatives
- 14.15.5 Regulations
- 14.15.6 Regulatory Bodies
- 14.15.7 Major Associations
- 14.15.8 Taxes Levied
- 14.15.9 Corporate Tax Structure
- 14.15.10 Investments
- 14.15.11 Major Companies
14.16 Canada MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Major Companies
15.3 South America MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.6 South America MASH Treatment Market: Country Analysis
15.7 Brazil Market
15.8 Brazil MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.10 Brazil MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Major Companies
16.3 Middle East MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Major Companies
17.3 Africa MASH Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa MASH Treatment Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa MASH Treatment Market, Segmentation By Disease Stage, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

18.1 Company Profiles
18.2 Madrigal Pharmaceuticals Inc.
- 18.2.1 Company Overview
- 18.2.2 Products And Services
- 18.2.3 Business Strategy
- 18.2.4 Financial Overview
18.3 Novo Nordisk A/S
- 18.3.1 Company Overview
- 18.3.2 Products And Services
- 18.3.3 Financial Overview
18.4 Eli Lilly Company
- 18.4.1 Company Overview
- 18.4.2 Products And Services
- 18.4.3 Business Strategy
- 18.4.4 Financial Overview
18.5 AstraZeneca plc
- 18.5.1 Company Overview
- 18.5.2 Products And Services
- 18.5.3 Business Strategy
- 18.5.4 Financial Overview
18.6 Mayo Clinic
- 18.6.1 Company Overview
- 18.6.2 Products And Services
- 18.6.3 Financial Overview

19 Other Major And Innovative Companies

19.1 Zydus Lifesciences
- 19.1.1 Company Overview
- 19.1.2 Products And Services
19.2 King's College Hospital
- 19.2.1 Company Overview
- 19.2.2 Products And Services
19.3 Johns Hopkins Hospital
- 19.3.1 Company Overview
- 19.3.2 Products And Services
19.4 Imperial College Healthcare NHS Trust
- 19.4.1 Company Overview
- 19.4.2 Products And Services
19.5 Cleveland Clinic
- 19.5.1 Company Overview
- 19.5.2 Products And Services
19.6 HighTide Therapeutics Inc.
- 19.6.1 Company Overview
- 19.6.2 Products And Services
19.7 Sagimet Biosciences
- 19.7.1 Company Overview
- 19.7.2 Products And Services
19.8 Rivus Pharmaceuticals
- 19.8.1 Company Overview
- 19.8.2 Products And Services
19.9 89bio Inc.
- 19.9.1 Company Overview
- 19.9.2 Products And Services
19.10 Dr. Falk Pharma
- 19.10.1 Company Overview
- 19.10.2 Products And Services
19.11 Akero Therapeutics
- 19.11.1 Company Overview
- 19.11.2 Products And Services
19.12 NorthSea Therapeutics BV
- 19.12.1 Company Overview
- 19.12.2 Products And Services
19.13 Lipocine Inc.
- 19.13.1 Company Overview
- 19.13.2 Products And Services
19.14 Cirius Therapeutics
- 19.14.1 Company Overview
- 19.14.2 Products And Services
19.15 Alimentiv Inc.
- 19.15.1 Company Overview
- 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 GlaxoSmithKline (GSK) Acquired efimosfermin From Boston Pharmaceuticals
22.2 Gilead Sciences Acquired CymaBay Therapeutics

23 Recent Developments In MASH Treatment

23.1 Home-Based Therapeutic Approach Gains Traction In MASH Management
23.2 Next-Gen FGF21 Therapy Under Investigation For MASH Management

24 Opportunities And Strategies

24.1 MASH Treatment Market In 2029 - Countries Offering Most New Opportunities
24.2 MASH Treatment Market In 2029 - Segments Offering Most New Opportunities
24.3 MASH Treatment Market In 2029 - Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies

25 MASH Treatment Market, Conclusions And Recommendations

25.1 Conclusions
25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People

26 Appendix

26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer